Latest News for: inhibitor

Edit

ProJenX Announces a Development Update for Prosetin, a First-in-Class, CNS-Penetrant MAP4K Inhibitor

PR Newswire 16 Jun 2026
... selective, CNS-penetrant MAP4K inhibitor—in participants with ALS ... Prosetin is a potent, selective, CNS-penetrant, orally available MAP4K inhibitor under evaluation for the potential treatment of ALS.
Edit

Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization (Onco-Innovations Ltd)

Public Technologies 16 Jun 2026
("Kuano"), supporting the continued advancement of Onco's PNKP Inhibitor Technology (also known as ONC010) through advanced AI-enabled and quantum-based computational approaches.
Edit

Luye Pharma Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China (Luye Pharma Group Ltd)

Public Technologies 16 Jun 2026
In addition, LY03021, which is a first-in-class GABAAR PAM/NET/DAT inhibitor intended to treat major depressive disorder, is progressing through Phase 1 clinical development.
Edit

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference

PR Newswire 16 Jun 2026
"A unique inhibitor conformation selectively targets Gram+ Bacterial DNA Replication" at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference on June 11, 2026.
Edit

Atom Therapeutics to Update Clinical Trials of Its Lead Drugs, a URAT1 Inhibitor for Chronic ...

The Milton Standard Journal 15 Jun 2026
HANGZHOU, China--(BUSINESS WIRE)--Jun 15, 2026-- ....
Edit

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers (IDEAYA Biosciences Inc)

Public Technologies 15 Jun 2026
) IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties IDE892 has a CYP3A4 IC50 greater than 45 ...
Edit

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

PR Newswire 15 Jun 2026
IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties IDE892 has a CYP3A4 IC50 greater than 45 ...
Edit

Vanflyta® Approved in China as First and Only FLT3 Inhibitor for Patients with Newly Diagnosed FLT3-ITD Positive AML (Daiichi Sankyo Co Ltd)

Public Technologies 15 Jun 2026
) Vanflyta® Approved in China as Firs t and Only FLT3 Inhibitor for Patients with Newly Diagnosed FLT3-ITD Pos itive AML ... Vanflyta is a FLT3 inhibitor being developed and commercialized by Daiichi Sankyo (TSE.
Edit

EGFR Inhibitors Market to Witness Upsurge in Growth at a CAGR of 7.9% During the Forecast Period (2026-2036) Owing to the Entry of Next-generation TKIs, ADCs, and Combination Strategies with Immunotherapy| DelveInsight

PR Newswire 15 Jun 2026
Scope of the EGFR Inhibitors Market Report EGFR Inhibitors Patient Population Forecast EGFR Inhibitors Therapeutics Market Size EGFR Inhibitors Pipeline Analysis EGFR Inhibitors Market Size and Trends ...
Edit

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with ...

The Essex Reporter 14 Jun 2026
LLY) today announced new data from the Phase 1 AJX-101 ...
Edit

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

PR Newswire 13 Jun 2026
AJX-101 is the first clinical trial to evaluate a type II selective JAK2 inhibitor in patients with myelofibrosis ... Patients had received a median of two prior therapies, and all had previously received a type I JAK2 inhibitor.
Edit

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology ...

Nasdaq Globe Newswire 12 Jun 2026
-�JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - ... .
Edit

Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor

The Eagle-Tribune 12 Jun 2026
... an oral, potent and selective STAT6 inhibitor, is .
Edit

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026

The Eagle-Tribune 12 Jun 2026
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - ... .
Edit

Recludix Pharma to Present Preclinical Asthma and Dermatitis Data for Oral STAT6 Inhibitor REX-8756 at ...

Nasdaq Globe Newswire 12 Jun 2026
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for ...

Article Search

tools
×
×
×
×